The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)

NCT04405739 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

71

Enrollment

INDUSTRY

Sponsor class

Conditions

SARS-CoV 2

Interventions

DRUG: EIDD-2801
DRUG: Placebo

Sponsor

Ridgeback Biotherapeutics, LP

Collaborators

[object Object]